Table 1

Characteristics of 12 (among 996) patients who died during or within the 12 weeks following direct-acting antivirals (DAAs) therapy for HCV chronic infection

PatientAge at deathSexFibrosis stageRegimen (weeks)Timing of deathCause of death
182MCirrhosis child C10SOF+SMV (10)W10HCC
276FCirrhosis child B7SOF+DCV (12)W12Encephalopathy
365MF2+SOF+SMV (12)W12Sudden death
455MCirrhosis child ASOF+LDV+RBV (8)W8Sudden death
568FCirrhosis child CSOF+DCV (20)FU W4Encephalopathy, sepsis and metastatic breast cancer
658FCirrhosis child B2D+RBV (6)W6Liver failure
769MCirrhosis child ASOF+DCV (24)FU W4Sepsis
856MCirrhosis child B7SOF+DCV (24)FU W10Haemorrhagic stroke
967MCirrhosis child C10SOF+TLV (12)FU W11Haemorrhagic stroke
1068MF3SOF+LDV (5)W5Sudden death
1171FF3SOF+LDV (12)FU W7Sepsis with toxic medullar aplasia
1271FF1/cryoglobulinaemiaGZP+ELV (12)FU W12Peritonitis on diverticulitis
  • 2D, ombitasvir/paritaprevir/ritonavir; DCV, daclatasvir; ELV, elbasvir; FU, follow-up; GZP, grazoprevir; HCC, hepatocellular carcinoma; LDV, ledipasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; TLV, telaprevir; W, week.